Evidence map›Paper›PMID 42440766›Full record

ArticleRSC advances2026

Quasi-static and dynamic compressive mechanical properties of amino acid ionic liquid-doped mixed-matrix membranes.

Duoyi Fang

Abstract read
In one paragraph

Article in RSC advances, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author.

Duoyi FangSchool of Civil Engineering and Mechanics, Lanzhou University Lanzhou 730000 China fangdy2023@lzu.edu.cn.ORCID https://orcid.org/0009-0006-4509-3791

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In this study, taking Matrimid®5218 and Pebax 1657 as polymer matrices, the amino acid ionic liquid (AAIL) [EMIm]Gln was incorporated to construct mixed-matrix membranes (MMMs), with the aim of systematically elucidating their quasi-static and dynamic mechanical responses. Fourier transform infrared spectroscopy (FT-IR), X-ray diffraction (XRD), scanning electron microscopy (SEM), and thermogravimetric analysis (TGA) were used to characterize the functional groups, chain packing, morphology, and thermal stability of the membranes. These analyses were further integrated with nanoindentation, dynamic mechanical analysis (DMA), and uniaxial tensile testing to comprehensively evaluate local compressive behavior, viscoelastic response, and large-deformation fracture characteristics. The results demonstrate that the incorporation of [EMIm]Gln did not alter the fundamental structural framework of the membranes, but significantly enhanced segmental chain mobility. For the pristine Matrimid® membrane, the Young's modulus and hardness were 2.84 GPa and 126 MPa, respectively, which decreased to 2.21 GPa and 86 MPa after doping with 20 wt% [EMIm]Gln. In the Pebax-based MMMs, these values declined from 0.42 GPa and 28 MPa to even lower levels. DMA results further revealed that the glass transition temperature of the Matrimid®-based MMMs decreased from 310 °C to 283 °C, while the Pebax-based MMMs exhibited a continuous reduction in storage modulus accompanied by an increase in loss modulus. Overall, the introduction of [EMIm]Gln shifted the membranes from a "high-rigidity, low-energy-dissipation" regime toward a "low-rigidity, high-toughness" regime. Notably, Matrimid® was more sensitive to plasticization, whereas Pebax exhibited a stronger capacity to accommodate the ionic liquid. These findings provide a mechanistic basis for selecting suitable AAIL loadings in mechanically reliable mixed-matrix membranes.

Identifiers

PMID42440766
PMCPMC13334383

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.